

The "Smart Pill" A Safer Approach for Aspirin Therapy

POZEN's patented "smart pill" concept combines an immediate-release proton pump inhibitor (PPI) with a pH-sensitive coated aspirin. With the coordinated release of the active ingredients in a single tablet, the PA product platform (the name referring to the PPI and Aspirin) is intended to significantly reduce gastrointestinal ulcers and complications compared to an aspirin taken alone.

Many epidemiology studies have shown a significant decline in the risk of cancer with increasing aspirin use for colon, breast, lung and prostate cancer.


Safer Aspirin: Potential New Treatment For Heart Disease and Stroke

Despite recent medical research advances, heart disease, stroke and other cardiovascular diseases remain the number one and most costly cause of death in men and women in the United States according to the American Heart Association (AHA). Nearly 2,500 Americans die of cardiovascular disease each day, an average of one death every 35 seconds. In addition, cardiovascular disease claims more lives each year than the next four leading causes of death combined, which are cancer, chronic lower respiratory disease, accidents and diabetes mellitus.

The AHA recommends aspirin therapy for patients who are at higher risk and have experienced a heart attack, unstable angina, ischemic stroke (caused by a blood clot) or transient ischemic attacks (or "little strokes"). This recommendation is based on sound evidence from clinical trials demonstrating that aspirin aids in preventing the recurrence of heart attack, hospitalization for recurrent angina, and second strokes. Additionally, the AHA cites medical studies showing aspirin helps prevent these events from occurring in people at high risk.

POZEN's PA product candidate is being developed to provide patients with a safer aspirin that can be taken

PA 32520 28 Day Proof of Concept Study "Safer Aspirin"



- Expected Benefits
 - Significant reduction of GI damage vs. aspirin alone
 - Cardiovascular protection
 - Potential reduction in risk of colorectal cancer - evidence growing in additional tumor types
- Patent issued 2005 - expires 2023

on a chronic basis for cardiovascular prevention -- reducing the historical NSAID-associated gastrointestinal damage and complications.

"Safer Aspirin" - Development Timeline

POZEN conducted a proof-of-concept studies with its PA product candidate with positive results. These results can be found under "Development Program-PA" within the "Product Candidates" section of our website.

Emerging Colorectal Cancer Benefits

Research continues to point to the various benefits of aspirin therapy, including studies published in medical journals highlighting its potential role in the reduction in the recurrence of colorectal cancer. An article in the March 2003 issue of the New England Journal of Medicine expanded on this, by stating that the prevention of adenomas (precursors of most colorectal cancers) will most likely also prevent colorectal cancer.

According to the American Cancer Society, colorectal cancer is the third most common cancer found in men and women in this country. In 2007, the organization estimates approximately 112,340 new cases of colon cancer in the United States will be identified.